Creo Medical Group PLC Director/PDMR Shareholding (2492A)

TIDMCREO

RNS Number : 2492A

Creo Medical Group PLC

22 December 2017

Creo Medical Group plc (the "Company")

Director/PDMR Dealing

The Company announces that it has received notice of exercise of options ("Options") under the Company's EMI Share Option Scheme from Steven Morris, Chief Operating Officer, a PDMR, to subscribe for 115,000 Ordinary Shares of GBP0.001 each in the Company (the "New Ordinary Shares"). The exercise price of the Options is 15.56 pence each.

Following the exercise of these Options Mr Morris will hold 115,000 Ordinary Shares in the Company representing approximately 0.1423 per cent. of the Company's issued share capital.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on or around 3 January 2018.

Following the issue of the New Ordinary Shares the Company's total issued share capital will consist of 80,826,745 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares the total number of voting rights in the Company is 80,826,745. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ----------------------------------------------------------- 
 a)   Name                       Steven Morris 
---  -------------------------  -------------------------------- 
 2    Reason for the notification 
---  ----------------------------------------------------------- 
 a)   Position/status            Chief Operating Officer 
---  -------------------------  -------------------------------- 
 b)   Initial notification       Initial 
       /Amendment 
---  -------------------------  -------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ----------------------------------------------------------- 
 a)   Name                       Creo Medical Group plc 
---  -------------------------  -------------------------------- 
 b)   LEI                        213800H188ZDCWWXFA21 
---  -------------------------  -------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ----------------------------------------------------------- 
 a)   Description of 
       the financial               Ordinary shares of GBP0.001 
       instrument, type            each 
       of instrument 
 
       Identification              GB00BZ1BLL44 
       code 
---  -------------------------  -------------------------------- 
 b)   Nature of the              Exercise of shares options 
       transaction 
---  -------------------------  -------------------------------- 
 c)   Price(s) and volume(s)       Price(s)           Volume(s) 
                                   -----------------  ---------- 
 
                                     Exercise of 
                                     shares options 
                                     at 15.56p per 
                                     share              115,000 
                                   -----------------  ---------- 
---  -------------------------  -------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume 
                                   Weighted average price of 
                                   15.56 per share 
       - Price 
---  -------------------------  -------------------------------- 
 e)   Date of the transaction    22 December 2017 
---  -------------------------  -------------------------------- 
 f)   Place of the transaction   Off Market 
---  -------------------------  -------------------------------- 
 

Contacts

 
 Creo Medical:                   Cenkos:             FTI Consulting: 
 Richard Rees                    Camilla Hume/Mark   Brett Pollard 
  [phone]             Connelly (NOMAD)    / Mo Noonan 
  [e-mail]    Michael Johnson     [phone] 
                                  / Russell Kerr      1000 
                                  (Sales)             [e-mail] 
                                  [phone] 
                                  8900 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFIFFELFFID

(END) Dow Jones Newswires

December 22, 2017 07:10 ET (12:10 GMT)